CAS Number65-45-2
Synonymsortho-hydroxybenzamide; EINECS 200-609-3; 2-hydroxy-benzamide; Cidal; OHb; o-Hydroxybenzamide; salicylamide; hydroxybenzamide; hydroxyphenylamide; Benzamide,2-hydroxy; 2-Hydroxybenzolcarboxamid; Allevin; MFCD00007978; 2-hydroxybenzamide; Salicylic acid amide; 2-Carbamoylphenol; Algiamida; Algamon
Molecular Formula2-(HO)C6H4CONH2
Molecular Weight137.14
Purity99%
Density1.3±0.1 g/cm3
Boiling Point279.7±42.0 °C at 760 mmHg
Melting Point140-144 °C (lit.)
Appearancesolid
EINECS200-609-3
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 65-45-2 |
| Catalog No. | 2A-9016919 |
| Chinese Name | 水杨酰胺 |
| Synonyms | ortho-hydroxybenzamide; EINECS 200-609-3; 2-hydroxy-benzamide; Cidal; OHb; o-Hydroxybenzamide; salicylamide; hydroxybenzamide; hydroxyphenylamide; Benzamide,2-hydroxy; 2-Hydroxybenzolcarboxamid; Allevin; MFCD00007978; 2-hydroxybenzamide; Salicylic acid amide; 2-Carbamoylphenol; Algiamida; Algamon |
| Molecular Formula | 2-(HO)C6H4CONH2 |
| Molecular Weight | 137.14 |
| Purity | 99 |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 279.7±42.0 °C at 760 mmHg |
| Melting Point | 140-144 °C (lit.) |
| Appearance | solid |
| Water Solubility | methanol: 0.1 g/mL, clear | <0.1 g/100 mL at 20 ºC |
| Storage Condition | This product should be sealed, dry and protected f |
| Packaging | III |
| Application | Salicylamide is a microsomal UDP-glucuronosyltransferase inhibitor. Salicylamide is an analgesic and antipyretic agent. |
| EINECS | 200-609-3 |
| HTC | 2924299090 |
| PubChem ID | 24888510 |
| MDL Number | MFCD00007978 |
| SMILES | NC(=O)c1ccccc1O |
| InChI | 1S/C7H7NO2/c8-7(10)5-3-1-2-4-6(5)9/h1-4,9H,(H2,8,10) |
| InChI Key | SKZKKFZAGNVIMN-UHFFFAOYSA-N |
| Beilstein/REAXYS | 742439 |
| NACRES Code | NA.22 |
| UNSPSC | 12352100 |
| Hazard Symbols | 6.1(b) |
| MSDS | msds/16919_1_65_45_2.pdf |
| Bioactivity | Salicylamide is an inhibitor of microsomal UDP-glucuronosyltransferase. Salicylamide is an analgesic and anti-pyretic agent. Related Catalog Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology In Vitro Treatment with salicylamides leads to the bacterial growth inhibition which correlates with the level of inhibition of sulfate reduction[1]. In Vivo Salicylamide administration decreases the levels of radiosulfate in maternal serum and placenta, and impaires the incorporation of radiosulfate into fetal skeletal GAGs. Salicylamide administration results in a decrease in the calcium content of fetal limb bones, but has no significant effect on maternal serum calcium[2]. Salicylamide administration decreases radiosulfate uptake by maternal serum and liver, fetus and placenta--effects being dose-dependent. Differences in radiosulfate uptake by the fetus and placenta over time, induced by salicylamide, are also significant independently of maternal serum levels of radiosulfate[3]. Animal Admin Rats: Pregnant rats are fed 25% casein diet with or without 2% salicylamide from day 6 to day 17 or day 19 of gestation. The dams are killed on day 17 or day 19 of gestation, 24 hours following an intramuscular injection of sodium 35S-sulfate[2]. References [1]. Kushkevych I, et al. Activity of selected salicylamides against intestinal sulfate-reducing bacteria. Neuro Endocrinol Lett. 2015;36 Suppl 1:106-13. [2]. Halstead PK, et al. Effect of salicylamide on skeletal glycosaminoglycan sulfation and calcification in fetal rat limbs. Drug Nutr Interact. 1981;1(1):75-86. [3]. Knight E, et al. Effect of salicylamide on the placental transfer and fetal tissue distribution of sodium-35S-sulfate in the rat. J Nutr. 1978 Feb;108(2):216-25. Chemical & Physical Properties Density 1.3±0.1 g/cm3 Boiling Point 279.7±42.0 °C at 760 mmHg Melting Point 140-144 °C(lit.) Molecular Formula C7H7NO2 Molecular Weight 137.136 Flash Point 122.9±27.9 °C Exact Mass 137.047684 PSA 63.32000 LogP 1.11 Vapour Pressure 0.0±0.6 mmHg at 25°C Index of Refraction 1.579 InChIKey SKZKKFZAGNVIMN-UHFFFAOYSA-N SMILES NC(=O)c1ccccc1O Storage condition Refrigerator Stability Stable. Light sensitive. Incompatible with strong bases, strong oxidizing agents. Water Solubility methanol: 0.1 g/mL, clear | <0.1 g/100 mL at 20 ºC |
| Use of | Salicylamide is an inhibitor of microsomal UDP-glucuronosyltransferase. Salicylamide is an analgesic and anti-pyretic agent. Properties Articles35 Name salicylamide Synonym More Synonyms Salicylamide Biological Activity Description Salicylamide is an inhibitor of microsomal UDP-glucuronosyltransferase. Salicylamide is an analgesic and anti-pyretic agent. Related Catalog Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology In Vitro Treatment with salicylamides leads to the bacterial growth inhibition which correlates with the level of inhibition of sulfate reduction[1]. In Vivo Salicylamide administration decreases the levels of radiosulfate in maternal serum and placenta, and impaires the incorporation of radiosulfate into fetal skeletal GAGs. Salicylamide administration results in a decrease in the calcium content of fetal limb bones, but has no significant effect on maternal serum calcium[2]. Salicylamide administration decreases radiosulfate uptake by maternal serum and liver, fetus and placenta--effects being dose-dependent. Differences in radiosulfate uptake by the fetus and placenta over time, induced by salicylamide, are also significant independently of maternal serum levels of radiosulfate[3]. Animal Admin Rats: Pregnant rats are fed 25% casein diet with or without 2% salicylamide from day 6 to day 17 or day 19 of gestation. The dams are killed on day 17 or day 19 of gestation, 24 hours following an intramuscular injection of sodium 35S-sulfate[2]. References [1]. Kushkevych I, et al. Activity of selected salicylamides against intestinal sulfate-reducing bacteria. Neuro Endocrinol Lett. 2015;36 Suppl 1:106-13. [2]. Halstead PK, et al. Effect of salicylamide on skeletal glycosaminoglycan sulfation and calcification in fetal rat limbs. Drug Nutr Interact. 1981;1(1):75-86. [3]. Knight E, et al. Effect of salicylamide on the placental transfer and fetal tissue distribution of sodium-35S-sulfate in the rat. J Nutr. 1978 Feb;108(2):216-25. Chemical & Physical Properties Molecular Formula C7H7NO2 Exact Mass 137.047684 PSA 63.32000 Index of Refraction 1.579 InChIKey SKZKKFZAGNVIMN-UHFFFAOYSA-N Storage condition Refrigerator Stability Stable. Light sensitive. Incompatible with strong bases, strong oxidizing agents. |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 30.0% |
| Transport Info | Product name: Chemical name |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Amytal sodium | 64-43-7 | 2A-9016903 |
| Diethyl sulfate | 64-67-5 | 2A-9016904 |
| Iodoacetic acid | 64-69-7 | 2A-9016905 |
| rac-Falcarinol | 4117-12-8 | 2A-9016914 |
| Gallamine triethiodide | 65-29-2 | 2A-9016917 |
| 4-Aminosalicylic acid | 65-49-6 | 2A-9016922 |
| N-Acetyl-L-methionine | 65-82-7 | 2A-9016924 |
| Orotic acid | 65-86-1 | 2A-9016926 |
| Uracil | 66-22-8 | 2A-0201793 |
| Acetylcholine bromide | 66-23-9 | 2A-9016929 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS